Skip to main content
All lobbying filings

ABBVIE, INC.

Lobbying for ABBVIE INC.

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$1,160,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • GAVIN PROFFITT New on this filing
    Previously held: Professional Staff Member (6/2018-1/2020) for the House Republican Study Committee; Professional Staff member (2/2023-6/2025) for the House Committee on Energy and Commerce; Health Policy Advisor (6/2025-4/2026) for Senator Ron Johnson

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Copyright/Patent/Trademark

S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

Health Issues

S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications

Medicare/Medicaid

Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment

Taxation/Internal Revenue Code

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

Labor Issues/Antitrust/Workplace

Issues related to antitrust and competition policy

Trade (domestic/foreign)

Issues related to pharmaceutic tariffs and unfair trade practices Issues related to U.S. biotech competitiveness with China

 Bills named in this filing 9
  • S. 1040
    Drug Competition Enhancement Act
  • S. 864
    HELP Copays Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • S. 2903
    Safe Step Act
  • H.R. 5509
    Safe Step Act
  • H.R. 5376
    Impacts and Outcomes for Health Career Training Act
  • H.R. 1328
    Supply Chain Security and Growth Act of 2025
  • H.R. 1990
    American Innovation and R&D Competitiveness Act of 2025
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem